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Abstract
Introduction Caring for a person with Parkinson’s disease (PD) is associated with an increased risk of psychiatric morbidity 
and persistent distress. The objective of this study was to describe the burden and the related factors of caregivers of advanced 
PD (APD) patients either treated with continuous dopaminergic delivery systems or standard therapy.
Methods This cross-sectional, epidemiologic study conducted in 13 Italian sites enrolled PD patients treated with continu-
ous dopaminergic delivering systems [either levodopa/carbidopa intestinal gel (LCIG) infusion or continuous subcutaneous 
apomorphine infusion (CSAI)] or continuation of standard of care (SOC) with a caregiver. Patient quality of life (QoL) and 
caregiver burden were assessed using the Parkinson’s Disease Questionnaire (PDQ-8) and Zarit Burden Inventory (ZBI), 
respectively.
Results 126 patients (mean age 69.3 ± 8 years) and their caregivers (mean age 57.9 ± 12.9) were enrolled. Most caregiv-
ers were spouses. Fifty-three patients were treated with LCIG, 19 with CSAI, and 54 with SOC. Mean ZBI scores were 
29.6 ± 14.4 for LCIG, 35.8 ± 20.2 for CSAI, and 31.4 ± 16.0 for SOC. Caregivers of LCIG, CSAI, and SOC patients showed 
no burden or mild/moderate burden in 74, 53, and 63% of the cases, respectively. Mean PDQ-8 scores were 11.25 ± 5.67, 
11.26 ± 5.55, and 14.22 ± 6.51 in LCIG, CSAI, and SOC patients. Neurologists considered patients “very much or much 
improved” in 89, 58, and 13% of the LCIG, CSAI, and SOC groups using the Clinical Global Impression–Global Improve-
ment Scale. Predictors significantly associated with caregiver burden were patients and caregivers’ judgment of QoL and 
caregivers’ need to change work.
Conclusions Caregiver burden showed a tendency to be lower when patients are treated with LCIG than with CSAI or SOC.
Keywords Advanced Parkinson’s disease · Levodopa/carbidopa · Intestinal infusion · Caregiver burden · Quality of life
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder 
characterized by troublesome motor and non-motor com-
plications, with a progressive loss of autonomy in per-
forming basic activities of daily living, which negatively 
impacts quality of life (QoL) [1]. Recent data showed that 
the main motor symptoms impacting the health-related 
QoL of patients with PD include dyskinesia, motor fluctua-
tions, axial impairment, and freezing of gait [2]. Regarding 
non-motor symptoms (NMS), depression, dementia, psy-
chosis, cognitive impairment, apathy, and sleep disorders 
were found to be the most common determinants in reduc-
ing QoL and increasing disability [3–5].
Due to the progressive disease course, there is an 
increasing utilization of economic and social resources. 
Indeed, patients often require caregiver assistance for 
daily activities, personal safety, medication compliance, 
and social involvement, with a consequent impact on car-
egiver burden and QoL [4–8]. Most PD patients are cared 
for in their own home and spouses are the main informal 
caregivers [6]. Caring for a partner or family member with 
a progressive neurologic disease has been recognized to 
negatively impact a caregiver’s physical, emotional, and 
psychosocial well-being, with an increased risk of psy-
chiatric morbidity and persistent distress [9–11]. More-
over, caregiver burden increases as a patient’s disease 
progresses, with speech difficulties and cognitive deterio-
ration associated with poorer caregiver QoL [11–13].
Due to the aging population and related increasing 
emergence of chronic neurologic diseases, caregiver bur-
den has become a major issue. However, few studies have 
examined the identification of factors that affect the stress 
and QoL of caregivers in PD. Further, modifications in 
QoL are better perceived by the caregiver rather than the 
patient, due to the cognitive impairment that may arise 
as the disease progresses [14]. Moreover, the role of the 
caregiver becomes progressively important throughout the 
disease course, when motor and non-motor complications 
occur and disease management becomes more complex.
During the advanced PD (APD) stage, motor and NMS, 
including autonomic and psychological complaints and 
postural instability, require continuous adjustment of dif-
ferent medications, such as levodopa, dopamine agonists, 
catechol-o-methyltransferase inhibitors, and type B mono-
amine oxidase inhibitors [2, 15].
Even in the presence of motor fluctuations and disabling 
dyskinesia, many APD patients still continue to be treated 
with standard of care (SOC). A recent survey indicated 
that approximately 90% of APD patients were taking PD 
medication 5–9 times per day; 10% were taking medica-
tion > 10 times per day [16]. The same study showed that 
only 4% of APD patients were very satisfied with their 
conventional PD therapy [16]. Adequate management of 
intricate therapeutic schedules is essential to preserve 
satisfactory QoL in the advanced disease stage; however, 
this usually requires complex disease management, includ-
ing frequent medication adjustments [2, 15]. Therapeutic 
options in APD include device-aided interventions, such 
as deep brain stimulation (DBS), continuous subcutaneous 
apomorphine infusion (CSAI), and levodopa/carbidopa 
continuous intestinal infusion gel (LCIG).
This study was designed to describe the burden and the 
related factors of caregivers of APD patients either treated 
with continuous dopaminergic delivery systems (CSAI or 
LCIG) or SOC.
Patients and methods
Study design
This observational study was conducted at 13 Movement 
Disorder (MD) centers in Italy, according to a cross-sec-
tional design. Consecutive APD patients and their caregiv-
ers were recruited during routine follow-up visits planned 
at the MD centers.
Patient selection
Inclusion criteria were the presence of a familial (non-pro-
fessional) adult caregiver who had provided regular daily 
assistance (≥ 3 h per day) to the patient for ≥ 6 months; 
adult patients with APD in treatment with any of the fol-
lowing: (1) optimized infusion therapies (LCIG or CSAI) 
started ≥ 6 months before enrollment but ≤ 3 years or (2) 
continuing oral SOC who were offered but refused LCIG 
or CSAI or who had a ≥ 3-h OFF period per day or > 25% 
of daily time spent in OFF as assessed by United Parkin-
son’s Disease Rating Scale (UPDRS)-IV item 39.
Exclusion criteria included: patient history or presence 
of any severe condition that might interfere with caregiver 
burden assessments; patients with DBS; previous treat-
ment with LCIG, CSAI, or DBS; mild to severe cognitive 
dysfunction/dementia (i.e., Mini-Mental State Exami-
nation score < 24 or per clinical judgment), and stage 5 
Hoehn & Yahr (H&Y) in OFF in the past 12 months.
The present study was approved by the ethics commit-
tee of each local health authority. Each patient provided 
informed consent. The study was conducted according 
to the International Conference on Harmonisation Good 
Clinical Practices.
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Assessments
The primary endpoint of this study was to evaluate car-
egiver burden and its related factors among caregivers of 
APD patients using the Zarit Caregiver Burden Interview 
(ZBI) score. The ZBI assesses the impact of the disease on 
caregiver’s emotional, physical, social, and financial well-
being [17] using a 22-item questionnaire with a 5-point 
scale, from 0 (never) to 4 (nearly always) [6]. The ZBI 
total score is categorized as follows: 0–20 (little or no bur-
den), 21–40 (mild to moderate burden), 41–60 (moderate 
to severe burden), and 61–88 (severe burden). Scores were 
further aggregated into two categories: ZBI total score 
from 0 to 40 (little-to-moderate burden) and from 41 to 
88 (moderate to severe burden).
Parkinson’s disease features
Data collected from PD patients (CSAI/LCIG and SOC 
groups) included socio-demographic characteristics, 
comorbidities, drugs and drug regimens, disease staging 
(H&Y), disease onset, motor fluctuations, time spent in 
OFF, non-motor symptoms, levodopa equivalent daily 
dose (LEDD, calculated using the levodopa equivalent 
calculator, http://www.parki nsons measu remen t.org), and 
reason for switching to infusion therapies or for remain-
ing in SOC. Information about the source of first knowl-
edge about advanced treatment options, patient’s working 
capacity, and working habits changes was also collected.
Measures on caregiver and economic resources
Demographic characteristics of caregivers included rela-
tionship with patient, educational level and employment 
status were collected. Caregivers were asked to complete a 
qualitative survey to understand the burden due to familial 
assistance, working capacity, and working habits changes. 
Physicians provided paper questionnaires to caregivers in 
an envelope and instructed them to complete the question-
naire in the outpatient room.
Measures of quality of life and treatment 
satisfaction
Patient satisfaction with the current treatment and car-
egivers’ judgement on their life perception and social 
adaptation were collected. Patient-reported quality of 
life measure includes the disease-specific eight-item Par-
kinson’s Disease Questionnaire (PDQ-8) [18]; clinicians 
completed the Clinical Global Impression–Improvement 
Scale (CGI-I) to assess the effectiveness of current treat-
ment [19].
Statistical analysis
The per-protocol population (PP) was defined as all-enrolled 
subjects without a main protocol violation. All statistical 
tables, figures, and analyses were produced using  SAS® for 
Windows release 9.4 (64-bit) or later (SAS Institute Inc., 
Cary, NC, USA). Patient and caregiver profile data were 
analyzed only in PP population by means of descriptive 
statistics. Whenever necessary, normality was assessed by 
means of the Shapiro–Wilk test and with graphical methods. 
In case of non-normality, appropriate transformation of data 
was applied or a nonparametric test/model was adopted. A 
two-sided p < 0.05 was considered statistically significant.
In all the analyses involving ZBI total score, only ques-
tionnaires with responses to ≥ 18 of 22 questions were used, 
according to copyright holder instructions [17]. For miss-
ing data (in case of only ≤ 4 missing questions), the aver-
age scores from valid responses were rounded to the nearest 
integer and used to complete any missing fields. To evaluate 
differences in the burden, stress, and QoL of caregivers of 
patients either treated with a continuous dopaminergic deliv-
ery system (LCIG or CSAI) or SOC, the ZBI total score in 
the two treatment groups (“standard treatment” vs “LCIG/
CSAI”) was compared by means of an analysis of variance 
(ANOVA) for unbalanced data. The ANOVA (GLM—Gen-
eralized Linear Models) model was fitted to evaluate ZBI 
total score differences.
The ZBI total score was analyzed by means of Pearson/
Spearman correlation coefficient in its correlation with: age 
of patient and of caregiver, PD duration, duration of motor 
fluctuation, daily time spent in OFF, in motor fluctuations, 
in dyskinesia, CGI-I rate, and PDQ-8 total score. The Pear-
son test was used in case of normal distribution of both the 
considered variables. The normality of variables distribution 
was assessed by means of Shapiro–Wilk test.
An ANOVA (GLM) model was fitted to evaluate ZBI 
total score differences and to compute a correlation ratio 
with regards to each of the following single factors: gender 
of patient and of caregiver, presence of PD-associated symp-
toms, caregiver’s duration of assistance, caregiver’s change 
in work, caregiver’s change in capability to perform family 
duties and leisure activities, need of professional assistance, 
H&Y stage, caregiver’s time spent per day for assistance, 
UPDRS-IV item 39, patient’s judgment on QoL, subject’s 
working capacity, number of outpatient visits (access to 
emergency department hospitalizations in the past 6 months 
due to PD), caregivers’ judgment on their QoL, and on their 
capability to perform family duties and leisure activities 
under the present treatment.
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In the multiple regression model, only the variables sig-
nificantly associated (p < 0.25) with the caregiver burden 
(ZBI total score) were considered.
Determination of sample size
A sample size of 120 caregivers/subjects (unbalanced 
according to a 1:2 ratio, 40 on SOC and 80 on CSAI or 
LCIG) was calculated to estimate a statistically significant 
difference in the mean ZBI score equal or superior to 13 
points, with the assumptions of 80% power, alpha 0.05, and 
a standard deviation (SD) of 25. At the time of the protocol 
writing, only a previous study showed a pre-post difference 
of more than 22 points with a standard deviation of approx. 
13 points during a prospective assessment with LCIG [20]. 
No other data were available for the other populations under 
study.
To avoid major bias in the selection of the population, the 
sites were asked to consecutively enroll all subjects that met 
the inclusion criteria attending outpatient visits.
Results
Demographics and clinical characteristics
Enrollment was performed from September 2014 to Septem-
ber 2015. Of the 131 patients enrolled, 5 were excluded from 
the analysis due to protocol violations; thus, 126 patients 
were included in the PP population (53, 19, and 54 patients 
in the LCIG, CSAI, and SOC groups).
Demographic characteristics of patients and caregivers, 
including relationship with patient, caregiver’s educational 
level, patient’s and caregiver’s employment status, are sum-
marized in Table 1. There were no significant differences in 
age and gender between groups.
Most caregivers were women (69.84% of the total 
cases; mean age 57.94 ± 12.9 years) taking care of spouses 
(60.32%), followed by sons/daughters (31.75%). The major-
ity of caregivers (92%) were providing assistance to the 
patient for ≥ 12 months, with 53.17% of them caregiving 
24 h a day (day and night; Table 1).
The clinical characteristics for each treatment group are 
reported in Table 2. The age at PD diagnosis was similar in 
the three groups, while disease duration was significantly 
longer in the LCIG group (16.38 ± 5.8 years) compared 
with the SOC group (12.83 ± 5.08 years; p = 0.0003). Simi-
larly, the duration of motor fluctuations was significantly 
higher in the LCIG group (8.36 ± 4.8 years) than in the SOC 
group (difference vs LCIG group, − 3.14 years; p < 0.0001) 
and CSAI group (difference vs LCIG group, − 2.89 years; 
p = 0.0099), as reported in Table 2. In the LCIG group, the 
duration of daily motor fluctuations was significantly lower 
(50%) compared with the SOC group (p < 0.0001), as were 
OFF periods (75 and 40% less in the LCIG group than the 
SOC and CSAI groups; p < 0.0001; Table 2). Similarly, 81% 
of LCIG patients had < 25% of daily time spent in OFF as 
assessed by UPDRS-IV item 39, while 82% of the SOC 
patients showed more time spent in OFF (26% up to 75% of 
the day). In the CSAI group, 47% of the patients had < 25% 
of daily time spent in OFF (Table 2). The H&Y staging dis-
tribution was different in the three groups of patients. In 
fact, in the LCIG group, 32% of the patients were in H&Y 
stage 2.5 and 40% were in H&Y stage 3, while 19 and 
65% of patients continuing SOC were in stages 2.5 and 3, 
respectively. Non-motor symptoms affected the majority of 
patients (99%), without significant differences among the 
three groups as reported in Table 2.
Caregiver burden and associated factors
Mean ZBI scores did not differ significantly across groups, 
though lower scores were detected in the LCIG group 
(29.6 ± 14.42) compared with the CSAI (35.8 ± 20.15; 
p = 0.328 vs LCIG) and SOC groups (31.4 ± 16; p = 0.535 
vs LCIG). The percentage of caregivers of LCIG patients 
showing no burden or little-to-moderate burden was higher 
(74%) than in the other groups (53 and 63% in the CSAI and 
SOC groups), but was not statistically significant (Fig. 1).
The Spearman correlation showed that the ZBI score was 
significantly correlated to the PDQ-8 score (p = 0.002), indi-
cating that the patient’s life perception is related to caregiver 
burden. A statistically significant correlation was found 
between ZBI score and the following variables: “caregiver’s 
change in capability to perform family duties and leisure 
activities” (p < 0.001) and “caregiver’s change in work” 
(p = 0.001), “need of professional assistance” (p = 0.019), 
“patient’s judgment on QoL” (p = 0.010), and “caregiver’s 
judgment on QoL” (p < 0.001; Table 3).
The multiple regression model showed a statistically sig-
nificant association between the ZBI total score and the fol-
lowing variables: “caregiver’s change in work” (p = 0.001), 
“patient’s judgment on QoL,” (p = 0.0456, but it loses its 
statistical significance when ranks are compared), and “car-
egiver’s judgment on QoL” (p = 0.003 and 0.005 “good vs 
very poor” and “very good vs very poor”; Table 3).
Patients’ treatment
The mean duration of continuous infusion at the time of 
the enrollment in the study was 17.8 ± 9.14 months in the 
LCIG group and 24.66 ± 9.94 in the CSAI group. The mean 
duration of LCIG infusion per day was 14.11 ± 2.08 h dur-
ing daytime at a lower LEDD compared with that reported 
in the CSAI group (1112.64 ± 473.36 mg for LCIG and 
1665.26 ± 1308.98 for CSAI; Table 4). As shown in Table 3, 
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LCIG patients took a lower total number of anti-parkinso-
nian concomitant medication units per day (1.43 ± 0.65) than 
CSAI patients (6.69 ± 4.42; p = 0.001).
The majority of patients in the LCIG and CSAI groups 
used oral levodopa before switching to the advanced 
treatment (94 and 100%, respectively), with a LEDD of 
972.5 ± 417.9 mg for the LCIG group and 1185 ± 686.3 
for the CSAI group, while dopamine agonists were 
used in approximately 60% of both groups (Table  5). 
In the SOC group, the mean daily number of levodopa 
tablets per day was 5.59 ± 1.8 units, with a mean LEDD of 
732.63 ± 230.1 mg.
Attitude towards advanced therapies
Regarding the source of knowledge on the MD center man-
aging the advanced treatment options reported by each 
treatment group, the main sources of information were 
community neurologists (26–40% of the cases) while patient 
associations as source of knowledge represented a small 
Table 1  Demographic characteristics of the patients and caregivers
LCIG levodopa/carbidopa intestinal gel, CSAI subcutaneous apomorphine infusion, SOC standard of care, SD standard deviation
LCIG (n = 53) CSAI (n = 19) SOC (n = 54)
Patients
 Demographics
  Age (years); mean ± SD (range) 70.26 ± 7.1 (53–84) 66.0 ± 6.6 (54–77) 69.57 ± 9.1 (42–88)
  Female; n (%) 28 (53%) 9 (47%) 25 (46%)
  Male; n (%) 25 (47%) 10 (53%) 29 (54%)
 Employment status; N (%)
  Worker 0 3 (16%) 5 (9%)
  Retired 45 (85%) 16 (84%) 48 (89%)
  House keeper 7 (13%) 0 1 (2%)
  Unemployed 1 (2%) 0 0
Caregivers
 Demographics
  Age (years); mean ± SD (range) 59.19 ± 13.2 (36–84) 60.26 ± 12.9 (29–78) 55.89 ± 12.6 (29–85)
  Female; n (%) 30 (56%) 15 (79%) 43 (80%)
  Male; n (%) 23 (43%) 4 (21%) 11 (20%)
 Patient relationship; N (%)
  Spouse 33 (62%) 13 (68%) 30 (56%)
  Son/daughter 16 (30%) 4 (21%) 20 (37%)
  Brother/sister 1 (2%) 0 3 (5%)
  Other relative 3 (6%) 2 (11%) 1 (2%)
 Educational level; N (%)
  Elementary/middle school 29 (55%) 9 (48%) 17 (31%)
  High school 20 (38%) 5 (26%) 28 (52%)
  Academic degree 4 (7%) 5 (26%) 9 (17%)
 Employment status; N (%) N = 51 N = 19 N = 54
  Worker 14 (27%) 5 (26%) 20 (37%)
  Retired 22 (43%) 7 (37%) 12 (22%)
  Student 0 1 (5%) 1 (2%)
  House keeper 13 (26%) 6 (32%) 16 (30%)
  Unemployed 2 (4%) 0 5 (9%)
 Caregiver assistance duration N = 52 N = 18 N = 53
  Since 6–12 months 7 (14%) 0 3 (6%)
  ≥ 12 months 45 (86%) 18 (100%) 50 (94%)
 Time spent during the day for the assistance N = 53 N = 19 N = 52
  Day and night (24 h) 26 (49%) 12 (63%) 29 (56%)
  During daytime 8 (15%) 4 (21%) 9 (17%)
  From 3 to 6 h per day 19 (36%) 3 (16%) 14 (27%)
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Table 2  PD clinical characteristics and PD-associated symptoms/comorbidities
LCIG (n = 53) CSAI (n = 19) SOC (n = 54) p value*,**
Age at PD diagnosis (years), mean ± SD, (range) 53.89 ± 9.1 (32–72) 52.42 ± 6.9 (40–62) 56.74 ± 9.4 (33–76) 0.524*
0.113**
PD duration (years), mean ± SD, (range) 16.38 ± 5.8 (7–33) 13.58 ± 4.1 (8–21) 12.83 ± 5.1 (4–35) 0.085*
0.0003**
Age at onset of motor fluctuations (years), mean ± SD, (range) 61.91 ± 8.8 (37–78) 60.53 ± 5.9 (52–72) 64.35 ± 9.4 (40–86) 0.529*
0.168**
Duration of motor fluctuations (years), mean ± SD, (range) 8.36 ± 4.8 (1–26) 5.47 ± 3.5 (2–14) 5.22 ± 4.1 (1–25) 0.0099*
 < 0.000**1
Duration of motor fluctuations (h/day), mean ± SD, (range) 2.69 ± 2.5 (0–11) 2.79 ± 1.5 (0–5) 5.42 ± 2.6 (1–14) 0.362*
 < 0.0001**
Duration of OFF periods (h/day), mean ± SD, (range) 1.38 ± 1.5 (0–6) 2.32 ± 1.7 (0–8) 5.47 ± 2.2 (3–12) 0.009*
 < 0.0001**
Duration of dyskinesia (h/day), mean ± SD, (range) 2.92 ± 3 (0–12) 2.79 ± 2 (0–8) 2.85 ± 3 (0–12) 0.5424*
0.7358**
UPDRS-IV Item 39, N (%)
 Not present 6 (11%) 1 (5%) 0 0.037*
< 0.001** 1–25% 37 (70%) 8 (42%) 9 (17%)
 26–50% 9 (17%) 8 (42%) 36 (67%)
 51–75% 1 (2%) 2 (11%) 8 (15%)
 76–100% 0 0 1 (2%)
Hoehn & Yahr in OFF, N (%) 0.121*
0.039** 1 1 (2%) 0 0
 1.5 2 (4%) 0 1 (2%)
 2 5 (9%) 2 (11%) 0
 2.5 17 (32%) 13 (68%) 10 (19%)
 3 21 (40%) 3 (16%) 35 (65%)
 4 7 (13%) 1 (5%) 8 (15%)
PD-associated symptoms N (%) 98% 100% 100% 0.547*
0.311**
 Falls 28 (54%) 11 (58%) 31 (57%) 0.704*
0.364**
 Confusion 18 (35%) 9 (47%) 17 (31%) 0.300*
0.784**
 Forgetfulness 17 (33%) 7 (37%) 18 (33%) 0.705*
0.890**
 Bladder control problems 26 (50%) 10 (53%) 27 (50%) 0.789*
0.922**
 Increased sweating 26 (50%) 12 (63%) 22 (41%) 0.291*
0.397**
 Sexual disturbances 10 (19%) 10 (53%) 20 (37%) 0.005*
0.036**
 Apathy 14 (27%) 9 (47%) 16 (30%) 0.093*
0.711**
 Having felt sad or in a depressed mood for longer than 2 weeks 13 (25%) 5 (26%) 14 (26%) 0.877*
0.868**
 Hallucinations 10 (19%) 2 (11%) 11 (20%) 0.403*
0.845**
 Anxiety 22 (42%) 12 (63%) 32 (59%) 0.105*
0.066**
 Cognitive function decline 19 (37%) 4 (21%) 16 (30%) 0.235*
0.493**
 Sleep disturbances 29 (56%) 11 (58%) 35 (65%) 0.811*
0.287**
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percentage of cases (4–11%; Table 6). Twenty-two percent 
of the caregivers assisting SOC patients declared that they 
had never received information about advanced therapies, 
while 43 and 35% were partially or constantly informed on 
this issue, respectively. Conversely, the majority of caregiv-
ers of LCIG or CSAI patients were fully informed about 
these treatments (Table 6).
Among patients receiving LCIG or CSAI, the main rea-
sons that convinced them to switch from SOC to an infu-
sion treatment were reduced QoL (79 and 84% in the LCIG 
and CSAI groups) or the presence of significant disability 
and loss of autonomy (85 and 68% in the LCIG and CSAI 
groups), as shown in Table 7. Conversely, the main reason 
why patients refused to initiate advanced therapies was fear 
to undergo invasive procedures (56% of the cases).
Clinical judgment and quality of life perception
Within each treatment group, both patients and their car-
egivers expressed a similar judgment on their life percep-
tion. In fact, caregivers of LCIG patients rated their cur-
rent life status as “good” or “very good” in the 74% of the 
cases, while such ratings were reported only by 47% of 
CSAI caregivers (p = 0.0375) and 50% of SOC caregivers 
(p = 0.117; Fig. 2a). Similarly, LCIG and CSAI patients 
rated their life as “good” or “very good” in 79 and 74% 
of the cases, respectively, with a lower percentage in the 
SOC group (35%). Moreover, 65% of the SOC patients 
described their life as “poor” or “very poor” (Fig. 2b). The 
clinicians considered 89% of the LCIG patients as “very 
much improved” or “improved,” with less improvement 
noted in the CSAI and SOC groups (58 and 13%, respec-
tively; Fig. 2c). When patients treated with a continuous 
dopaminergic delivering system and their caregivers were 
asked to self-assess their current life compared with the 
previous SOC according to a score rated from 0 (very neg-
ative) to 10 (very positive), the mean score was 7.21 for 
LCIG patients and 6.37 for CSAI patients (LCIG vs CSAI; 
p = 0.02). In a similar way, the mean score expressed by 
the caregivers was 7.37 and 6.59, respectively, in LCIG 
and CSAI caregivers (LCIG vs CSAI, p = 0.0135).
The mean PDQ-8 score was lower (indicating better QoL) 
in the LCIG and CSAI groups compared with the SOC group 
(11.25 ± 5.7 and 11.26 ± 5.6 vs 14.22 ± 6.5, respectively), 
with a statistically significant difference between LCIG and 
SOC (p = 0.013). Interestingly, as per the distribution of the 
single items of the PDQ-8 questionnaire reported in Fig. 3, 
LCIG patients had less difficulty getting around in public 
and felt less embarrassed in public compared with CSAI 
and SOC patients.
*LCIG vs CSAI; **LCIG vs SOC; NA, not available
Table 2  (continued)
LCIG (n = 53) CSAI (n = 19) SOC (n = 54) p value*,**
 Impulse control disorders 4 (8%) 4 (21%) 8 (15%) 0.108*
0.234**
 Fatigue 31 (60%) 15 (79%) 34 (63%) 0.111*
0.636**
Fig. 1  Distribution of ZBI-
subscores in the three groups of 
caregivers
32 32 30
42
21 33
23
32
33
4 16 4
0%
20%
40%
60%
80%
100%
LCIG CSAI SOC
%
 p
a
en
ts
 
lile or no burden (0-20) mild to moderate burden (21-40)
moderate to severe burden (41-60) severe burden (61-88)
 Journal of Neurology
1 3
Table 3  Correlation and association of ZBI score according to demographics and PD characteristics
ZBI total score and p value
 Spearman correlation
  Patient’s age (years) 0.906
  Caregiver’s age (years) 0.935
  PD duration (years) 0.811
  Duration of motor fluctuations (years) 0.729
  Duration of motor fluctuations (h/day) 0.736
  Duration of dyskinesias (h/day) 0.470
  Duration of OFF periods (h/day) 0.372
  CGI-I score 0.303
  PDQ-8 score 0.002
 ANOVA models (univariate)
  Patient’s gender 0.380
  Caregiver’s gender 0.093
  Presence of PD-associated symptoms 0.924
  Caregiver’s duration of assistance 0.347
  Caregiver’s change in work 0.001
  Caregiver’s change in capability to perform family duties/leisure activities < 0.001
  Need of professional assistance 0.019
  Hoehn & Yahr stage 0.848
  Caregiver’s time spent for assistance 0.168
  UPDRS-IV item 39 0.474
  Patient’s judgment on quality of life 0.010
  Caregiver’s occupational status 0.577
  No. of outpatient visits in the last 6 months due to PD 0.203
  No. of accesses to emergency departments in the last 6 months due to PD 0.757
  No. of hospitalizations in the last 6 months due to PD 0.415
  Caregiver’s judgment on quality of life < 0.001
Multiple regression linear analysis (model 
on ranks)
Estimate p value 95% CI
Lower limit Upper limit
Intercept 34.97 0.175 − 15.84 85.79
Caregiver’s change in work
 Change vs no change 23.57 0.001 10.38 36.76
Caregiver’s change in capability to perform family duties and leisure activities
 Change vs no change 9.21 0.072 − 0.83 19.25
Need of professional assistance
 Need vs no need 7.24 0.278 − 5.92 20.40
Patient’s judgment on quality of life
 Poor vs very poor 41.20 0.113 − 9.94 92.34
 Good vs very poor 31.23 0.234 − 20.49 82.94
 Very good vs very poor 21.88 0.416 − 31.28 75.04
Caregiver’s judgment on quality of life
 Poor vs very poor − 3.48 0.737 − 24.04 17.08
 Good vs very poor 0.003 − 53.28
 Very good vs very poor 0.005 − 59.01
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Discussion
This observational study showed that caregiver burden 
is mainly associated to PD patient’s QoL, caregiver’s 
change in ability to perform family duties and leisure 
activities, caregiver’s change in work, the need of profes-
sional assistance, and by patient and caregiver judgment 
on life perception. The mean level of burden in each group 
is found to be in line with the ZBI range of 14.9–35.0 
(SD = 9.9–18.7) reported in PD caregivers in previous 
studies [6]. We found a small reduction in caregiver burden 
in LCIG compared with CSAI and SOC caregivers. It is 
interesting to note that we found a mild level of caregiver 
burden (ZBI mean value = 29.6) in the LCIG group similar 
to that reported in recent studies (mean ZBI score varying 
from 21.8 to 28.3) where the caregivers had similar char-
acteristics in terms of age, gender, familial relationship, 
and caregiving duration but with a shorter patients’ PD 
duration (8–9.7 years) compared to our study’s LCIG 
group [7, 8, 21]. Even though LCIG patients had a signifi-
cantly higher disease duration (16.3 years) compared with 
CSAI or SOC patients (13.6 and 12.8 years, respectively) 
in our study, a higher level of caregiver burden was not 
documented. Moreover, these results take on more sig-
nificance considering that the majority of caregivers were 
providing assistance for a longer period of time and half-
invested 24 h per day in caregiving.
The PREDICT study also confirmed that a high percent-
age of patients in advanced stage disease (80% in H&Y 
stage 3 or 4) continues to be treated with SOC (> 5 oral 
levodopa units per day), even if most of them spent > 50% 
Table 4  Advanced therapeutic scheme in the two groups (LCIG and CSAI)
Parameter LCIG (N = 53) CSAI (N = 19)
Duration of infusion (h/day); mean ± SD (range) 14.1 ± 2.1 (11.0–24.0) Not applicable
Levodopa equivalent daily dose (LEDD) (mg); mean ± SD (range) 1112.6 ± 473.4 (532–2960) 1665.3 ± 1309.0 (180–5600)
Duration of treatment (months); mean ± SD (range) 17.8 ± 9.1 (5.98–41.89) 24.7 ± 9.9 (5.65–40.15)
Patients using concomitant anti-parkinson medications during the day; N (%) 14 (26.4%) 13 (68.4%)
Number of anti-parkinson drug units/day; mean ± SD (range) 1.4 ± 0.7 (1–3) 6.7 ± 4.4 (1–19)
Table 5  Standard treatment 
before LCIG or CSAI 
implementation and in patients 
continuing with SOC
SD standard deviation
a Others in LCIG group = amantadine (n = 9), apomorphine pen (n = 1), rasagiline (n = 1), rotigotine (n = 1)
b Others in the SOC group = amantadine (n = 11), levodopa/carbidopa/entacapone (n = 1), trihexyphenidyl 
hydrochloride (n = 1), clonazepam (n = 1)
Parameter N (%) No. of tablets/day 
(mean ± SD) (range)
LEDD (mg) (mean ± SD) (range)
Standard treatments before LCIG (N = 50)
 Oral levodopa 50 (94%) 6.0 ± 1.4 (2–9) 972.5 ± 417.9 (250–2350)
 Dopamine agonists 33 (62%) 1.5 ± 0.7 (1–3) 274.6 ± 123.9 (100–560)
 COMT inhibitors 23 (43%) 4.3 ± 1.9 (1–10) 322.6 ± 230.8 (100–1200)
 MAO inhibitors 17 (32%) 1.1 ± 0.2 (1–2) 100.0 ± 0.0 (100–100)
 Othersa 12 (23%) 2.6 ± 2.4 (1–10) 204.3 ± 108.3 (100–360)
Standard treatments before CSAI (N = 19)
 Oral levodopa 19 (100%) 6.3 ± 1.8 (4–10) 1185 ± 686.3 (500–2500)
 Dopamine agonists 12 (63%) 2.4 ± 2 (2–8) 437.2 ± 596.5 (105–2000)
 COMT inhibitors 13 (68%) 4.4 ± 1.8 (2–8) 442.7 ± 403.1 (75–1400)
 MAO inhibitors 3 (16%) 1 ± 0 (1–1) 100 ± 0 (100–100)
 Amantadine 1 (5%) 2 200 (200–200)
Standard treatments in SOC-continuing patients (N = 54)
 Oral levodopa 54 (100%) 5.6 ± 1.8 (2–12) 732.6 ± 230.1 (200–1200)
 Dopamine agonists 36 (67%) 1.4 ± 1.2 (1–8) 211.6 ± 81.0 (100–360)
 COMT inhibitors 20 (37%) 4.5 ± 1.4 (2–7) 548.7 ± 414.0 (132–1400)
 MAO inhibitors 19 (35%) 1.3 ± 1.2 (1–6) 237.5 ± 388.9 (100–1200)
 Othersb 15 (28%) 2.3 ± 1.3 (1–5) 293.2 ± 443.9 (100–1625)
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of daily time in the OFF state, with poor QoL in 65% of the 
patients in SOC and 41% of their caregivers, in addition to 
poor QoL reported by the treating physician. This finding is 
particularly relevant considering that the recently published 
Navigate-PD consensus reported that non-invasive therapies 
may be judged insufficiently when QoL becomes inadequate 
due to motor fluctuations with or without dyskinesias, and 
the clinician and patients agree that non-invasive therapy 
alone is no longer effective [22].
It is also interesting to note that, in our study, patients 
continuing with SOC were receiving > 5 oral levodopa 
intakes per day. This, together with the daily time spent in 
OFF, would be a reason to consider these patients as pos-
sible candidates for advanced therapies, as reported by the 
Table 6  Source of knowledge for patients and caregiver on the advanced therapies and on MD implementing centers
LCIG (N = 53) CSAI (N = 19) SOC (N = 54)
Information on MD centers
 General practitioner 11 (21%) 4 (21%) 13 (24%)
 Community neurologist 21 (40%) 5 (26%) 15 (28%)
 Media 7 (13%) 1 (5%) 5 (9%)
 Patients’ association 2 (4%) 2 (11%) 4 (7%)
 Others patients 13 (25%) 6 (32%) 12 (22%)
 Other sources of information 11 (21%) 5 (26%) 12 (22%)
LCIG (N = 53) CSAI (N = 19) SOC (N = 51)
Caregivers knowledge on advanced treatments
 Constantly informed 38 (72%) 17 (89%) 18 (35%)
 Partially informed 13 (26%) 2 (11%) 22 (43%)
 Not informed 2 (4%) 0 11 (22%)
Source of first information received on advanced PD treatment options
Neurologist of the MD center 41 (77%) 16 (84%)
Community neurologist 7 (13%) 0
Media 1 (2%) 0
Other patients 2 (4%) 3 (16%)
General Practitioner 1 (2%) 0
Table 7  Reasons for change from standard treatment to LCIG or CSAI and reasons to remain in SOC
Reasons for patients who decided to switch LCIG (N = 53) CSAI (N = 19)
N (%) N (%)
Caregiver was willing and available to assist patient in managing the advanced PD treatment 
for a long period
36 (68%) 14 (74%)
The patient could no longer tolerate poor quality of life 42 (79%) 16 (84%)
The patient presented significant disabilities, with serious loss of autonomy 45 (86%) 13 (68%)
The caregiver wished to reduce the stress he/she was undergoing 8 (15%) 3 (16%)
The patient and/or caregiver showed interest in advanced treatment options 23 (43%) 9 (47%)
Complexity of conventional treatments/scarce compliance 10 (19%) 3 (16%)
Reasons for patients to remain in standard treatment SOC (N = 54)
N (%)
The caregiver was not willing or available to assist patient in managing the advanced PD treatment for a long period 8 (15%)
The patient is afraid of advanced treatments 30 (56%)
The caregiver is worried for the patient 14 (26%)
The patient believes his or her conditions are not debilitating such as to require an advanced therapy 21 (39%)
The caregiver believes that advanced therapies have to be considered in the very late stage of disease 17 (31%)
The physician believes that the patient is unsuitable for an advanced therapy 17 (31%)
SOC patients who were proposed in the past an advanced therapy but they refused for any reason 18 (33%)
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Navigate-PD consensus and Delphi panel [22, 23]. In fact, 
we also showed that patients switched to LCIG or CSAI 
were, on average, receiving six levodopa intakes per day. 
Both the consensus and the Delphi panel reported that 
patients requiring levodopa > 5 times daily, who have severe, 
troublesome OFF periods (> 1–2 h/day) despite optimal 
oral/transdermal levodopa or non–levodopa-based thera-
pies, should be referred for specialist assessment, even if 
disease duration is < 4 years. It is also interesting to note 
that, in our study, some APD patients were receiving SOC 
and did not receive information about the possibility of dis-
ease management in MD centers. In fact, we found that this 
role is primarily devolved to community neurologists or MD 
specialists.
The main reason that patients receiving SOC did not 
switch to an advanced therapy was fear (56% of the cases); 
the main reasons for choosing advanced therapy were poor 
QoL, and the significant disability and loss of autonomy 
(approximately 80% of the patients).
It has been recently reported that NMS, sleep problems 
in particular, have a higher impact on caregiver burden and 
caregiver QoL than motor symptoms [24, 25]. Schrag et al. 
reported that 40% of caregivers experienced a deterioration 
in health due to NMS [11]. In our study, NMS, including 
sleep problems, fatigue, falls, urinary dysfunction, sweat-
ing, and anxiety, were frequently reported in each patient 
group. Notwithstanding the presence of NMS, 74% of LCIG 
caregivers expressed a good or very good perception of their 
own well-being, while in the CSAI and SOC groups, the 
percentages were lower. More caregivers of SOC patients 
were dissatisfied (41%) compared with those caring for 
LCIG patients (26%). The result obtained in LCIG caregiv-
ers is interesting, considering that > 50% of the caregivers 
of patients receiving DBS rated their subjective well-being 
as negative after 1 year of follow-up (especially if older and 
more depressed) [26]. In this study, patient QoL was signifi-
cantly better in the LCIG and CSAI groups compared with 
the SOC group according to PDQ-8 scores. The improve-
ment in QoL under LCIG over 24 months, using the PDQ-
8, has been also recently reported in the GLORIA registry 
[27]. Moreover, both LCIG and CSAI patients had QoL 
that was good or very good, whereas 65% of SOC patients 
had poor or very poor QoL. These data are consistent with 
those reported by a Swedish survey on 3326 PD subjects, 
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indicating that 67% of APD patients were unsatisfied with 
SOC [16].
Previous authors have reported that integrated clinical 
management of families with PD patients has become much 
more challenging from the physician’s perspective [26]. 
The development and introduction of new technologies 
and medications has been accompanied by strong involve-
ment of patients and their families in overall care. Family 
members are more aware of the disease and treatment, and 
express their opinions and preferences at every step of the 
disease course. Therefore, the modern approach to PD man-
agement should include continuous engagement of patients 
and caregivers [13, 28]. This involves a redefinition of the 
patient–doctor relationship, creating a model of participa-
tory medicine, with shared decision-making and helps pro-
vide care that is respectful of individual patient preferences 
and needs, including consensus on treatments to implement 
[29].
Limitations and strengths
Our study extends knowledge on caregiver burden in APD. 
As reported in previous studies [6, 11], patient QoL is one of 
the main influencing factors of caregiver burden and the ZBI 
questionnaire should be considered as a valid instrument to 
assess the burden of PD. The main limitation of this study 
is its cross-sectional design, which did not allow considera-
tion of the evolution of the burden of care and a comparison 
with baseline condition before treatment initiation, although 
data of the multiple regression analysis confirm the solidity 
of our findings. Moreover, the limited sample size in the 
CSAI group did not allow for a robust comparison with the 
LCIG group.
Another limitation of the study was the heterogeneous 
distribution of the H&Y stage in the three groups, which 
could have influenced both patients’ and caregivers’ answers. 
To limit this bias, we decided not to enroll patients in H&Y 
stage 5, because the answer given by the caregiver could 
be exclusively influenced by the disabling condition of the 
patient. Moreover, patients in H&Y stage 5 have a great dif-
ficulty in reaching the hospital to be routinely visited. Also 
the exclusion of patients with dementia or severe cognitive 
dysfunction could represent a further limitation.
Conclusions
In summary, our study on caregiver burden offers interesting 
insights on the role of caregivers. Caregiver burden tends 
to be lower in familiars who assist patients treated with 
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advanced therapies. Patient’s quality of life is frequently 
associated to caregiver burden which should be taken into 
account in the long-term management of PD.
Further research will help clarify whether the use of 
advanced therapies could reduce caregiver distress and the 
use of adjunctive socioeconomic resources.
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